Enclomiphene Citrate vs AndroGel: Head-to-Head Efficacy Comparison

How Enclomiphene and AndroGel Work Through Opposite Mechanisms

These two drugs reach the same destination by completely different routes. Enclomiphene citrate, the trans-isomer of clomiphene, blocks estrogen receptors in the hypothalamus and pituitary. This blockade removes negative feedback, causing a rise in gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) 1. The elevated LH then drives the Leydig cells in the testes to produce more testosterone endogenously. The HPG axis stays active.

AndroGel (testosterone 1% or 1.62%) works on the other side of the equation entirely. It delivers synthetic testosterone directly through the skin into the bloodstream 2. The exogenous testosterone itself feeds back to the hypothalamus and pituitary, suppressing GnRH, LH, and FSH. Testicular function declines. Spermatogenesis slows or stops.

This mechanistic split matters for every downstream clinical decision. If the HPG axis is intact and the goal is to raise testosterone while keeping the reproductive system functional, enclomiphene preserves that architecture. If testosterone production is fundamentally impaired at the testicular level, or if fertility is not a concern, exogenous replacement with AndroGel bypasses the axis altogether. The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy notes: "In men who desire fertility, testosterone therapy should not be used as it suppresses spermatogenesis. Alternatives such as selective estrogen receptor modulators... may be considered" 3.

Testosterone Restoration: What the Clinical Data Shows

Both drugs get testosterone into the normal range. The question is how they compare on magnitude and consistency.

In the ZA-305 phase 3 trial, enclomiphene citrate 25 mg daily raised mean total testosterone from a baseline of approximately 228 ng/dL to 445 ng/dL at 16 weeks. The 12.5 mg dose achieved similar but slightly lower results 4. Kim et al. reported that men with secondary hypogonadism treated with enclomiphene achieved mean testosterone levels of 464 ng/dL, restoring values to the eugonadal range while maintaining gonadotropin levels well above baseline 1.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with testosterone below 275 ng/dL, found that AndroGel 1% raised median testosterone from 232 ng/dL to 470 ng/dL at 12 months 2. Sexual function, walking distance, and mood all showed improvements over placebo, though the magnitude of mood benefit was modest.

The testosterone numbers look remarkably similar on paper. Both therapies land most men in the 400-550 ng/dL window. But there are differences in variability. Gel absorption depends on application site, skin condition, sweating, and showering timing. Some men are poor absorbers. Enclomiphene absorption is more predictable as an oral medication, though its ceiling depends on how much testosterone the testes can produce in response to gonadotropin stimulation. Men with primary hypogonadism (testicular failure) will not respond well to enclomiphene because the machinery it signals is damaged 3.

Fertility Preservation: The Clinical Divider

This is where the comparison stops being close. Fertility preservation separates these two drugs more than any other variable.

AndroGel suppresses the HPG axis. Within 4 to 6 weeks of starting exogenous testosterone, LH and FSH drop toward undetectable levels. Spermatogenesis declines in parallel. A 2019 systematic review and meta-analysis found that exogenous testosterone reduced sperm concentration by an estimated 90% in most men, with 65% of users reaching azoospermia (zero sperm) within 6 months of initiation 5. Recovery after discontinuation typically takes 6 to 18 months, though some men experience prolonged or incomplete recovery.

Enclomiphene preserves spermatogenesis by design. Because it raises FSH alongside LH, the Sertoli cells in the testes continue receiving the signal to support sperm production. Wiehle et al. demonstrated that men on enclomiphene 25 mg maintained sperm concentrations above 20 million/mL throughout treatment, while men in the topical testosterone comparator arm saw sperm counts decline to oligospermic or azoospermic levels 6. FSH levels rose by approximately 50% in the enclomiphene group and fell by over 90% in the testosterone arm.

Dr. Robert Tan, a clinical endocrinologist involved in enclomiphene research, has stated: "For younger hypogonadal men who want to preserve their option to father children, enclomiphene offers something that no form of exogenous testosterone can provide: a meaningful rise in testosterone without shutting down the testicular axis."

For men in their 20s, 30s, or early 40s who have not yet completed their families, this distinction is not minor. It is the entire clinical conversation.

Estradiol, SHBG, and Hormonal Balance

Testosterone is only one piece of the hormonal picture. Both drugs affect estradiol (E2) and sex hormone-binding globulin (SHBG) differently, and those differences matter for symptom resolution.

Enclomiphene tends to increase estradiol. This makes physiological sense: as intratesticular testosterone rises, more substrate becomes available for aromatase conversion. In the ZA-305 trial, mean estradiol rose from approximately 20 pg/mL to 30-35 pg/mL, staying within the normal male reference range for most participants 4. SHBG also tends to rise modestly with enclomiphene, which can limit the increase in free testosterone despite higher total T values.

AndroGel's effect on estradiol is dose-dependent and varies with body composition. Men with higher body fat percentage convert more applied testosterone to estradiol via peripheral aromatization. The TTrials reported that testosterone gel raised estradiol levels proportionally, though individual variability was high 2. Some men require an aromatase inhibitor co-prescription if estradiol climbs above 50-60 pg/mL and symptoms of estrogen excess appear. SHBG tends to decrease with exogenous testosterone, which can increase the proportion of free testosterone available.

The net effect: enclomiphene produces a more balanced but potentially less aggressive hormonal profile. AndroGel can achieve higher free testosterone levels in some men but may require closer estradiol monitoring.

Side-Effect Profiles Compared

Neither drug is side-effect-free, but the profiles differ in character.

AndroGel carries the risks common to all exogenous testosterone preparations. The FDA issued a black box warning regarding secondary exposure: women and children who contact application sites can develop virilization symptoms including body hair growth, acne, and premature puberty in children 7. Erythrocytosis (hematocrit elevation above 54%) occurs in roughly 5-10% of men on testosterone therapy and requires periodic blood draws. Acne, oily skin, and sleep apnea exacerbation are additional concerns. The 2018 Endocrine Society guideline recommends monitoring hematocrit at 3-6 months and then annually during testosterone therapy 3.

Enclomiphene's side-effect profile reflects its SERM mechanism. The most commonly reported adverse events in clinical trials included headache (5-8%), hot flashes (2-4%), and nausea (2-3%) 4. Visual disturbances, a known concern with racemic clomiphene (Clomid), appear to be less frequent with the isolated trans-isomer, though long-term safety data beyond 2 years remains limited. Enclomiphene does not cause erythrocytosis because testosterone rises are driven by endogenous production within physiological regulatory limits. There is no skin transfer risk.

One underappreciated difference: enclomiphene does not cause testicular atrophy. Men on exogenous testosterone frequently notice reduced testicular volume over months of treatment as the Leydig and Sertoli cells receive no stimulation. With enclomiphene, testicular volume is maintained or may even increase slightly due to elevated gonadotropin signaling 6.

Patient Selection: Who Gets Which Drug

The clinical decision tree is straightforward once you categorize the patient.

Choose enclomiphene when:

• The patient has secondary (central) hypogonadism with intact testicular function
• Fertility preservation is desired now or as a future option
• The patient prefers oral dosing over daily topical application
• The patient has household members (partners, children) at risk for testosterone transfer
• Baseline hematocrit is already elevated (above 50%), making exogenous testosterone riskier

Choose AndroGel when:

• The patient has primary hypogonadism (testicular failure) where gonadotropin stimulation will not produce adequate testosterone
• Fertility is not a concern (family complete, vasectomy, or no plans for children)
• The patient has tried SERMs without adequate testosterone response
• Rapid, reliable testosterone dosing with well-established pharmacokinetics is preferred
• The prescriber wants a therapy with decades of post-marketing safety data and clear FDA labeling

A third scenario exists. Some clinicians use enclomiphene as a bridge therapy for younger men, transitioning them to exogenous testosterone later if needed, or use it to restart the HPG axis after a period of exogenous testosterone use. The evidence supporting these approaches remains mostly observational, but the physiological rationale is sound 1.

Switching Between Enclomiphene and AndroGel

Switching direction matters. Going from AndroGel to enclomiphene requires a washout period to allow the suppressed HPG axis to begin recovering before enclomiphene can have an effect. Testosterone gel has an elimination half-life of approximately 10-100 hours depending on formulation, but HPG axis recovery typically takes 4 to 12 weeks after cessation of exogenous testosterone 3. During this period, men may experience a temporary dip in testosterone and associated symptoms.

Going from enclomiphene to AndroGel is simpler. Enclomiphene can be stopped and AndroGel started within days. There is no suppressed axis to recover. The main consideration is confirming that the switch is warranted, because a patient producing adequate endogenous testosterone on enclomiphene does not necessarily need exogenous replacement.

Monitoring during any transition should include total testosterone, free testosterone, LH, FSH, estradiol, and CBC at baseline and at 6-8 week intervals until stable.

Regulatory Status and Access

AndroGel has been FDA-approved since 2000 for male hypogonadism due to conditions such as Klinefelter syndrome, pituitary damage, or chemotherapy-related hypogonadism. It is available as a branded product and in generic testosterone gel formulations. Insurance coverage is common, though many plans require prior authorization with two morning testosterone levels below 300 ng/dL 7.

Enclomiphene citrate does not hold FDA approval as of mid-2026. It was previously under development by Repros Therapeutics (later acquired), but the FDA issued a complete response letter in 2015 requesting additional data. Despite lacking approval, enclomiphene is widely prescribed through compounding pharmacies and telehealth platforms. Compounded enclomiphene typically costs $30-90 per month out of pocket, which is comparable to generic testosterone gel copays for insured patients.

The lack of FDA approval means that long-term post-marketing safety surveillance data does not exist for enclomiphene in the same way it does for testosterone gel. Clinicians prescribing compounded enclomiphene are relying on phase 2/3 trial data, extrapolation from racemic clomiphene's decades of use, and growing clinical experience.

Direct Comparison: What No Head-to-Head Trial Has Confirmed

No large, randomized, head-to-head trial comparing enclomiphene citrate directly against AndroGel for all clinical endpoints has been published. The ZA-304 trial by Wiehle et al. included a topical testosterone comparator arm, but the primary design compared enclomiphene against placebo with the testosterone arm serving as an active reference 6. Results from that comparator arm showed similar testosterone normalization rates between enclomiphene and topical testosterone, with the fertility divergence described above.

Without a dedicated superiority or non-inferiority trial powered to detect differences in sexual function, energy, body composition, and bone density outcomes, any claim that one drug is "better" than the other across all metrics is premature. What the available data supports is this: both drugs raise testosterone similarly, but enclomiphene preserves fertility and avoids transfer risk, while AndroGel has a longer track record and works regardless of HPG axis integrity.

The Endocrine Society's 2018 guideline explicitly recommends against exogenous testosterone for men desiring fertility and lists SERMs as an alternative, noting: "Clinicians may offer clomiphene citrate... to men with hypogonadism who wish to preserve fertility, although this is an off-label use" 3. Enclomiphene represents the more targeted version of that recommendation, isolating the active isomer responsible for testosterone elevation while reducing the estrogenic side effects associated with the zuclomiphene isomer in racemic clomiphene.

Men starting testosterone replacement should have baseline semen analysis results documented if fertility is even a remote consideration. A total testosterone recheck at 6-8 weeks, along with LH, FSH, hematocrit, and PSA, establishes whether the chosen therapy is producing the intended hormonal shifts without safety signals.